Biolegend, 103121, Alexa Fluor® 488 anti-mouse CD45 Antibody, 25μg

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested SB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses
Excitation Laser: Blue Laser (488 nm)
Application Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
Additional Product Notes: Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Application References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Battis K, et al. 2022. J Neurosci. 42:7673. PubMed Abdel-Haq R, et al. 2022. Elife. 11:. PubMed Axelrod ML, et al. 2022. Nature. 611:818. PubMed Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed Fan Z, et al. 2023. Angiogenesis. . PubMed Gilman KE, et al. 2023. Cancers (Basel). 15:. PubMed Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed Fixsen BR, et al. 2023. Nat Immunol. . PubMed Preda MB, et al. 2021. Cell Death Dis. 12:566. PubMed Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed Wu Y, et al. 2021. Immunity. 54:2595. PubMed Wemlinger SM, et al. 2022. J Immunol. 208:1566. PubMed Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed Frederico B, et al. 2022. Dev Cell. 57:1957. PubMed Ullah I, et al. 2023. Cell Rep Med. 4:100893. PubMed Olivares-González L, et al. 2022. Antioxidants (Basel). 12: . PubMed Gilman KE, et al. 2023. Front Immunol. 13:1045710. PubMed Parida PK, et al. 2022. Cell Metab. 34:90. PubMed Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed Luff SA, et al. 2022. Nat Cell Biol. 24:616. PubMed Marko C, et al. 2014. Invest Ophthalmol Vis Sci . 55:291. PubMed Giorgetti E, et al. 2020. Cell Reports. 29(6):1539-1554.e7.. PubMed Kazakevych J, et al. 2020. Genome Biol. 21:64. PubMed Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed Logan C, Bowen C, and Menko A 2017. Sci Rep. . 10.1038/s41598-017-16456-5. PubMed Khandelwal P, et al. 2013. PLoS One. 8:64193. PubMed Masschelein E, et al. 2020. Skelet Muscle. 10:21. PubMed Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed Bornes L, et al. 2021. Life Sci Alliance. 4:00. PubMed Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed DeDreu J, et al. 2020. FASEB J. 34:9316. PubMed Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed Dubey LK, et al. 2019. Cell Rep. 27:2442. PubMed Yip HYK, et al. 2021. STAR Protocols. 2(3):100765. PubMed Chen I, et al. 2016. Sci Rep. 6:27195. PubMed Hallett JM, et al. 2022. Cell Stem Cell. 29:355. PubMed Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed Duarte J, et al. 2016. J Immunol. 197(12):4838-4847. PubMed Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed Gutknecht M, et al. 2017. Nat Commun. 10.1038/s41467-017-00488-6. PubMed Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed Mizbani A, et al. 2016. Development. 143: 4137 - 4148. PubMed Burns JC, et al. 2020. eLife. 9:00. PubMed Ferrari G, et al. 2011. Invest Ophthalmol Vis Sci. 52:2532. PubMed Wara AK, et al. 2020. Cell Rep. 33:108550. PubMed Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed Yip HYK, et al. 2020. Molecular Cell. 80(2):279-295.e8. PubMed Liu X, et al. 2020. Cell Host Microbe. 28(5):683-698.e6. PubMed Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed Lustgarten Guahmich N, et al. 2020. Angiogenesis. 23:443. PubMed Limbad C, et al. 2022. iScience. 25:103848. PubMed Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed Shibad V, et al. 2021. Front Immunol. 12:722451. PubMed Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed Li D, et al. 2022. Commun Biol. 5:271. PubMed Braun D, et al. 2013. J Biol Chem. 288:2689. PubMed Pang M, et al. 2009. J Immunol. 182:7001. PubMed Ding H, et al. 2016. Nat Commun. 7:11533. PubMed Wu X, et al. 2018. Cell. 172:423. PubMed von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed Franklin DA, et al. 2020. JCI Insight. 5:. PubMed Kazakevych J, et al. 2019. Sci Rep. 9:10410. PubMed Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed Reed-Geaghan EG, et al. 2020. J Exp Med. 217:00:00. PubMed Peng W, et al. 2018. Mol Cell Biol. 38:e00427. PubMed Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed Lasch M, et al. 2020. Front Physiol. 11:576736. PubMed DeDreu J, et al. 2022. FASEB J. 36:e21995. PubMed Li Q, et al. 2020. Am J Pathol. 190:2453. PubMed RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed Tian F, et al. 2016. Nat Commun. 7:13283. PubMed Lee EKS, et al. 2018. Cell Host Microbe. 23:121. PubMed Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed Ye Y, et al. 2011. Am J Physiol Lung Cell Mol Physiol. 300:L216. PubMed Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed Denk F, et al. 2016. Cell Rep. 15: 1771-1781. PubMed Qi S, et al. 2020. Theranostics. 10:1814. PubMed Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
RRID: AB_493532 (BioLegend Cat. No. 103121) AB_493531 (BioLegend Cat. No. 103122)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45 on UniProt.org
Clone: 30-F11
Regulatory Status: RUO
Other Names: T200, Ly-5, LCA
Isotype: Rat IgG2b, κ
Q: If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?
A: It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.
Q: Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?
A: Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.
Q: Are other fluorophores compatible with IBEX?
A: Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.
Q: The same antibody works in one tissue type but not another. What is happening?
A: Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.
Q: How can I be sure the staining I’m seeing in my tissue is real?
A: In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.